Martin K Bakht
Overview
Explore the profile of Martin K Bakht including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
15
Citations
202
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Chatterjee S, Linares J, Cid-Diaz T, Duran A, Khan M, Osrodek M, et al.
Nat Commun
. 2024 Nov;
15(1):9755.
PMID: 39567499
Overcoming resistance to therapy is a major challenge in castration-resistant prostate cancer (CRPC). Lineage plasticity towards a neuroendocrine phenotype enables CRPC to adapt and survive targeted therapies. However, the molecular...
2.
3.
Venkadakrishnan V, Presser A, Singh R, Booker M, Traphagen N, Weng K, et al.
Nat Commun
. 2024 Aug;
15(1):6779.
PMID: 39117665
Enhancer of zeste homolog 2 (EZH2) is a histone methyltransferase and emerging therapeutic target that is overexpressed in most castration-resistant prostate cancers and implicated as a driver of disease progression...
4.
Ku S, Wang Y, Garcia M, Yamada Y, Mizuno K, Long M, et al.
J Clin Invest
. 2024 Jul;
134(17).
PMID: 39024561
Notch signaling can have either an oncogenic or tumor-suppressive function in cancer depending on the cancer type and cellular context. While Notch can be oncogenic in early prostate cancer, we...
5.
Bakht M, Beltran H
Nat Rev Urol
. 2024 Jul;
22(1):26-45.
PMID: 38977769
Prostate-specific membrane antigen (PSMA) is an important cell-surface imaging biomarker and therapeutic target in prostate cancer. The PSMA-targeted theranostic Lu-PSMA-617 was approved in 2022 for men with PSMA-PET-positive metastatic castration-resistant...
6.
Venkadakrishnan V, Presser A, Singh R, Booker M, Traphagen N, Weng K, et al.
Res Sq
. 2024 Feb;
PMID: 38405800
Enhancer of zeste homolog 2 (EZH2) is a histone methyltransferase and emerging therapeutic target that is overexpressed in most castration-resistant prostate cancers and implicated as a driver of disease progression...
7.
Bakht M, Beltran H
Nat Cell Biol
. 2023 Dec;
25(12):1726-1728.
PMID: 38049603
No abstract available.
8.
Bakht M, Yamada Y, Ku S, Venkadakrishnan V, Korsen J, Kalidindi T, et al.
Nat Cancer
. 2023 Apr;
4(5):699-715.
PMID: 37038004
Tumor expression of prostate-specific membrane antigen (PSMA) is lost in 15-20% of men with castration-resistant prostate cancer (CRPC), yet the underlying mechanisms remain poorly defined. In androgen receptor (AR)-positive CRPC,...
9.
Bakht M, Hayward J, Shahbazi-Raz F, Skubal M, Tamura R, Stringer K, et al.
Proc Natl Acad Sci U S A
. 2022 Jan;
119(4).
PMID: 35064078
Prostate-specific membrane antigen (PSMA) is highly overexpressed in most prostate cancers and is clinically visualized using PSMA-specific probes incorporating glutamate-ureido-lysine (GUL). PSMA is effectively absent from certain high-mortality, treatment-resistant subsets...
10.
Bakht M, Lovnicki J, Tubman J, Stringer K, Chiaramonte J, Reynolds M, et al.
J Nucl Med
. 2019 Dec;
61(6):904-910.
PMID: 31806771
Although the incidence of de novo neuroendocrine prostate cancer (PC) is rare, recent data suggest that low expression of prostate-specific membrane antigen (PSMA) is associated with a spectrum of neuroendocrine...